NYSE: SOLVSolventum Corp Stock
$78.25+0.36 (+0.46%)
Updated Jul 2, 2025
SOLV Price
$78.25
Fair Value Price
N/A
Market Cap
$13.54B
52 Week Low
$47.16
52 Week High
$85.92
P/E
35.89x
P/B
4.15x
P/S
1.59x
PEG
0.82x
Dividend Yield
N/A
Revenue
$8.31B
Earnings
$379.00M
Gross Margin
54.6%
Operating Margin
8.99%
Profit Margin
4.6%
Debt to Equity
3.45
Operating Cash Flow
$772M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SOLV's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
A
SOLV
Ranked#12 of 42
Ranked#12 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.66 | A | |
| $17.41 | A | |
| $22.00 | B |
Be the first to know about important SOLV news, forecast changes, insider trades & much more!
SOLV News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SOLV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SOLV ($78.25) is trading above its intrinsic value of $46.57, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SOLV is poor value based on its earnings relative to its share price (35.89x), compared to the US market average (31.27x)
P/E vs Market Valuation
SOLV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SOLV due diligence checks available for Premium users.
Valuation
SOLV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
35.89x
Industry
43.75x
Market
31.27x
SOLV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SOLV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SOLV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.15x
Industry
4.02x
SOLV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SOLV price to earnings growth (PEG)
For valuing profitable companies with growth potential
SOLV is good value based... subscribe to Premium to read more.
PEG Value Valuation
SOLV's financial health
Profit margin
Revenue
$2.1B
Net Income
$137.0M
Profit Margin
6.6%
SOLV's Earnings (EBIT) of $747.00M... subscribe to Premium to read more.
Interest Coverage Financials
SOLV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.5B
Liabilities
$11.3B
Debt to equity
3.45
SOLV's short-term assets ($3.05B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SOLV's long-term liabilities ($8.70B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SOLV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$29.0M
Investing
-$114.0M
Financing
-$139.0M
SOLV's operating cash flow ($772.00M)... subscribe to Premium to read more.
Debt Coverage Financials
SOLV vs Health Information Service Stocks
Solventum Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.